Price
Financials
Consolidated, Rs crore| Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 11 | 22 | 40 | 43 | 60 |
| Expenses | 6 | 19 | 34 | 38 | 55 |
| Operating Profit | 5 | 3 | 6 | 6 | 5 |
| OPM % | 48% | 14% | 14% | 13% | 9% |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 5 | 3 | 6 | 5 | 5 |
| Tax % | 7% | 25% | 29% | 25% | 32% |
| Net Profit | 5 | 2 | 4 | 4 | 3 |
| EPS in Rs | 9.94 | 4.86 | 7.97 | 7.59 | 5.79 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 18 | 62 | 103 |
| Expenses | 16 | 53 | 92 |
| Operating Profit | 2 | 9 | 11 |
| OPM % | 13% | 14% | 11% |
| Other Income | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 2 | 9 | 10 |
| Tax % | 28% | 27% | 28% |
| Net Profit | 2 | 6 | 7 |
| EPS in Rs | 3.24 | 12.74 | 13.36 |
| Dividend Payout % | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | 67% | ||
| Compounded Profit Growth | % | % | % | 13% | ||
| Stock Price CAGR | % | % | % | -65% | ||
| Return on Equity | % | % | 20% | 21% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 5 | 5 | 5 |
| Reserves | 13 | 23 | 35 |
| Borrowings | 2 | 3 | 13 |
| Other Liabilities | 1 | 5 | 8 |
| Total Liabilities | 21 | 36 | 61 |
| Fixed Assets | 0 | 2 | 2 |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Other Assets | 20 | 33 | 59 |
| Total Assets | 21 | 36 | 61 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from Operating Activity | -4 | 1 | -13 |
| Cash from Investing Activity | -1 | -2 | -0 |
| Cash from Financing Activity | 13 | 3 | 5 |
| Net Cash Flow | 9 | 2 | -8 |
| Free Cash Flow | -4 | -0 | -14 |
| CFO/OP | -144% | 21% | -110% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 66 | 86 | 101 |
| Inventory Days | |||
| Days Payable | |||
| Cash Conversion Cycle | 66 | 86 | 101 |
| Working Capital Days | 187 | 86 | 126 |
| ROCE % | 35% | 26% |
| Mar 2024 | Sep 2024 | Mar 2025 | May 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Promoters | 67.96% | 67.96% | 67.03% | 62.24% | 62.24% | 62.24% |
| Public | 32.04% | 32.05% | 32.96% | 37.76% | 37.76% | 37.75% |
| No. of Shareholders | 251 | 260 | 325 | 335 | 410 | 416 |
Fundamentals
Market Cap₹ 47.1 Cr.
Current Price₹ 88.0
Stock P/E6.58
Book Value₹ 75.7
ROCE26.1 %
ROE21.0 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)67%
Compounded Profit Growth (TTM)13%
Consolidated figures.
Ownership
Promoter holding62.24% (-5.72 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | 544143 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -8.2% | -2.8% | -5.5 pts |
| 1 month | +5.9% | -6.8% | +12.7 pts |
| 3 months | -18.5% | -7.6% | -10.9 pts |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹60 Cr +445.5% vs Mar 2024.
Net profit ₹3 Cr -40.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Royal Sense Ltd?
Royal Sense Ltd (544143) has a market capitalisation of Rs 47.1 Cr. at the 2026-10-01 close.
What is the P/E ratio of Royal Sense Ltd?
Royal Sense Ltd trades at a P/E of 6.58 on trailing twelve-month profit, at the 2026-10-01 close.
What were Royal Sense Ltd's latest quarterly results?
In the Mar 2026 quarter, Royal Sense Ltd sales was Rs 60 Cr (+445.5% vs Mar 2024) and net profit was Rs 3 Cr.